Abstract:Diabetes, a chronic disease caused by genetic and environmental factors, threats the health of millions of people, which has become a global challenge. Therefore, much earlier intervention is required to prevent diabetes, type-2 diabetes particularly. Previous study revealed that glucagon-like peptide-1 is an intestine-derived insulinotropic hormone that stimulated glucose dependent insulin production and secretion from pancreatic 3-cells. Glucagon-like peptide-1 also exerted cytoprotective and antiapoptotic effects on 13-cells and decreased postprandial blood glucose via complicated mechanisms. However, glucagon-like peptide-1 was rapidly degraded and inactivated in vivo by the serine protease dipeptidyl peptidase4, which limited their ability to normalize blood glucose levels. Therefore, dipeptidyl peptidase-4 inhibitors could decrease the high levels of blood glucose in type 2 diabetes patients. In recent years, we have focused on synthesizing and evaluating the biological activities of novel xanthone compounds. Compound 9, a small xanthone derivative, was identified to show good dipeptidyl peptidase-4 inhibitory activity from high throughput screening (HTS) through varieties of xanthone derivatives and IC50 value against dipeptidyl peptidase-4 is 7.3 μg/mL (Fig. 1). Molecular docking study showed compound 9 could bind with the target enzyme and a pocket existed between the 7-substitued group and the target enzyme, which revealed that an adequate modification to compound 9 could Synthesis and Evaluation of Novel Xanthone Derivatives as Potent Dipeptidyl Peptidase-4 Inhibitors

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Seco-prolinenitrile Inhibitors of Dipeptidyl Peptidase IV Define Minimal Pharmacophore Requirements at P1.

Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-methanoprolinenitrile-based Inhibitors.

Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

An interdisciplinary approach provides insights into the pronounced selectivity of compound 42 for DPP9

Identification of Diverse Dipeptidyl Peptidase IV Inhibitors Via Structure-Based Virtual Screening

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Molecular Mechanistic Insights into Dipeptidyl Peptidase-IV Inhibitory Peptides to Decipher the Structural Basis of Activity

Synthesis, Biological Assay in Vitro and Molecular Docking Studies of New Imidazopyrazinone Derivatives As Potential Dipeptidyl Peptidase IV Inhibitors.

The Highly Potent and Selective Dipeptidyl Peptidase IV Inhibitors Bearing a Thienopyrimidine Scaffold Effectively Treat Type 2 Diabetes.

Substituted Piperidinyl Glycinyl 2-Cyano-4,5-methano Pyrrolidines As Potent and Stable Dipeptidyl Peptidase IV Inhibitors

Synthesis and Evaluation of Novel Xanthone Derivatives As Potent Dipeptidyl Peptidase-4 Inhibitors